Cyclic Triazole Compounds for Central Anti-Inflammatory Activity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing anti-inflammatory compounds do not effectively address the inflammatory processes associated with psychiatric and neurodegenerative diseases, lacking properties such as anti-inflammatory activity, bioavailability, solubility, cell membrane permeability, and safety.

Innovation Solution

Development of specific chemical compounds and pharmacologically acceptable salts with a novel structure, including 1,2,4-triazole derivatives, which exhibit enhanced anti-inflammatory activity, bioavailability, and improved safety profiles for treating inflammatory diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing anti-inflammatory compounds are used, then they have known pharmacological properties, but they lack effective anti-inflammatory activity against psychiatric and neurodegenerative diseases

Engineering Contradiction:
Improveanti-inflammatory activityVSAvoideffectiveness against psychiatric and neurodegenerative diseases
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by systematically modifying the chemical structure of triazole derivatives, specifically varying substituents at positions R1, R2, R3, R4, and R5 to optimize anti-inflammatory activity. The invention identifies specific structural parameters (such as aromatic heterocyclic groups, cycloalkyl groups, and their substitution patterns) that enhance effectiveness against central nervous system inflammation while maintaining peripheral anti-inflammatory properties.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite material principles by creating compounds with multiple functional groups combined in a single molecule. The triazole core structure is复合 with various aromatic heterocyclic groups, cycloalkyl groups, and substituent patterns to achieve multi-target activity against both peripheral and central inflammatory pathways, thereby addressing both psychiatric and neurodegenerative conditions.

Inventive Principle:
Principle #40Composite materials

2Reliability

If novel compound structures are developed, then anti-inflammatory activity and bioavailability are improved, but safety concerns may arise

Engineering Contradiction:
ImprovebioavailabilityVSAvoidsafety profile
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies self-service principles by designing compounds with metabolic stability features that allow the body to process and eliminate the drug through normal physiological pathways. The specific structural configuration of the triazole derivatives enables appropriate metabolism and excretion, ensuring that improved bioavailability does not lead to toxic accumulation.

Inventive Principle:
Principle #25Self-service

3Duration of action of moving object

If existing compounds are used, then they have established safety profiles, but they lack rapid onset and sustained efficacy

Engineering Contradiction:
Improvesustained efficacyVSAvoidonset of drug efficacy
Core Design Contradiction:
Duration of action of moving objectVSSpeed

Solution Approach 1:

The patent applies dynamics principles by creating compounds with optimized pharmacokinetic properties that enable both rapid absorption and sustained release. The molecular structure is designed to achieve appropriate solubility and membrane permeability for rapid onset, while metabolic stability ensures sustained efficacy over time.

Inventive Principle:
Principle #15Dynamics

Data Source

PatentEP3682881B1Compound having cyclic structure
Publication Date: 2026.04.01 DAIICHI SANKYO CO LTD
  • EP3682881B1 patent drawingFigure 1~2
  • EP3682881B1 patent drawingFigure 3~4
  • EP3682881B1 patent drawingFigure 5~6

AI summary

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., -CH2-, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.